{"text": ["AbbVie", "Is", "The", "Amazon", "Of", "Biopharma", "\u2014", "But", "Can", "It", "Keep", "Going?"], "created_at": "2018-05-24 20:14:49"}
{"text": ["IMBRUVICA\u00ae", "(ibrutinib)", "Plus", "GAZYVA\u00ae", "(obinutuzumab)", "Phase", "3", "iLLUMINATE", "Trial", "for", "First-Line", "Therapy", "of", "Chronic", "Lymphocytic", "Leukemia", "(CLL)", "Patients", "Met", "Primary", "Endpoint"], "created_at": "2018-05-24 13:00:00"}
{"text": ["Is", "the", "Options", "Market", "Predicting", "a", "Spike", "in", "AbbVie", "(ABBV)", "Stock?"], "created_at": "2018-05-24 12:35:12"}
{"text": ["Wired", "News", "\u2013", "CytomX", "Gets", "FDA", "Approval", "for", "Investigational", "New", "Drug", "Application,", "Triggers", "$25", "Million", "Milestone", "Payment", "from", "AbbVie"], "created_at": "2018-05-24 12:00:00"}
{"text": ["AbbVie", "Says", "Phase", "3", "ILLUMINATE", "Trial", "Met", "Primary", "Endpoint", "Of", "Improvement", "In", "PFS"], "created_at": "2018-05-24 09:08:00"}
{"text": ["AbbVie", "Says", "Phase", "3", "ILLUMINATE", "Trial", "Met", "Primary", "Endpoint", "Of", "Improvement", "In", "PFS"], "created_at": "2018-05-24 09:08:00"}
